Gommeren W[au] - Search Results

Year	Number of Results
1974	1
1975	1
1976	1
1978	4
1979	2
1981	3
1982	5
1983	5
1984	1
1985	1
1986	1
1987	2
1988	7
1991	2
1992	2
1993	2
1994	1
1995	1
1996	3
1997	2
1998	1
2000	3
2022	0

1

Receptor interactions of dopamine and serotonin antagonists: binding in vitro and in vivo and receptor regulation.

Leysen JE, Gommeren W, Janssen PF, Van Gompel P, Janssen PA. Leysen JE, et al. Among authors: gommeren w. Psychopharmacol Ser. 1988;5:12-26. doi: 10.1007/978-3-642-73280-5_2. Psychopharmacol Ser. 1988. PMID: 3045796 Review.

2

Biochemical profile of risperidone, a new antipsychotic.

Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA. Leysen JE, et al. Among authors: gommeren w. J Pharmacol Exp Ther. 1988 Nov;247(2):661-70. J Pharmacol Exp Ther. 1988. PMID: 2460616

3

Chronic neuroleptic treatment specifically alters the number of dopamine receptors in rat brain.

Theodorou A, Gommeren W, Clow A, Leysen J, Jenner P, Marsden CD. Theodorou A, et al. Among authors: gommeren w. Life Sci. 1981 Apr 6;28(14):1621-7. doi: 10.1016/0024-3205(81)90317-9. Life Sci. 1981. PMID: 7242249 No abstract available.

4

Genomic cloning, heterologous expression and pharmacological characterization of a human histamine H1 receptor.

De Backer MD, Gommeren W, Moereels H, Nobels G, Van Gompel P, Leysen JE, Luyten WH. De Backer MD, et al. Among authors: gommeren w. Biochem Biophys Res Commun. 1993 Dec 30;197(3):1601-8. doi: 10.1006/bbrc.1993.2662. Biochem Biophys Res Commun. 1993. PMID: 8280179

5

In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole.

Laduron PM, Janssen PF, Gommeren W, Leysen JE. Laduron PM, et al. Among authors: gommeren w. Mol Pharmacol. 1982 Mar;21(2):294-300. Mol Pharmacol. 1982. PMID: 6124876

6

Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors.

Chivers JK, Gommeren W, Leysen JE, Jenner P, Marsden CD. Chivers JK, et al. Among authors: gommeren w. J Pharm Pharmacol. 1988 Jun;40(6):415-21. doi: 10.1111/j.2042-7158.1988.tb06306.x. J Pharm Pharmacol. 1988. PMID: 2901473

7

Reconstitution of the human 5-HT(1D) receptor-G-protein coupling: evidence for constitutive activity and multiple receptor conformations.

Brys R, Josson K, Castelli MP, Jurzak M, Lijnen P, Gommeren W, Leysen JE. Brys R, et al. Among authors: gommeren w. Mol Pharmacol. 2000 Jun;57(6):1132-41. Mol Pharmacol. 2000. PMID: 10825383

8

Stable, high-level expression of human serotonin receptors in L929 cells using an inducible expression system.

Vanhoenacker P, Gommeren W, Luyten WH, Leysen JE, Haegeman G. Vanhoenacker P, et al. Among authors: gommeren w. Recept Channels. 1997;5(3-4):125-37. Recept Channels. 1997. PMID: 9606717

9

Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.

Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM. Leysen JE, et al. Among authors: gommeren w. Mol Pharmacol. 1985 Jun;27(6):600-11. Mol Pharmacol. 1985. PMID: 2860558

10

Non-serotonergic [3H]ketanserin binding sites in striatal membranes are associated with a dopac release system on dopaminergic nerve endings.

Leysen JE, Eens A, Gommeren W, Van Gompel P, Wynants J, Janssen PA. Leysen JE, et al. Among authors: gommeren w. Eur J Pharmacol. 1987 Feb 24;134(3):373-5. doi: 10.1016/0014-2999(87)90373-6. Eur J Pharmacol. 1987. PMID: 3569421 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results